# Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic Prostate Cancer

> **NCT00669162** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Kansas Medical Center** · enrollment: 27 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Docetaxel
- **RADIATION:** Radiation Therapy
- **DRUG:** Casodex and Zoladex (or Lupron)

## Key facts

- **NCT ID:** NCT00669162
- **Lead sponsor:** University of Kansas Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08
- **Primary completion:** 2016-08
- **Final completion:** 2017-04
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2019-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00669162

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00669162, "Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic Prostate Cancer". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT00669162. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*